Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Durchbruch. Durchbruch. Durchbruch. Kutcho Copper hat DAS Signal gesendet
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
48 Leser
Artikel bewerten:
(0)

Global Efficacy Testing Market 21018-2022 by Product and Service, Type, Application

DUBLIN, Feb. 7, 2018 /PRNewswire/ --

The "Efficacy Testing Market by Product and Service (Consumables, Services), Type (Antimicrobial Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharmaceutical Manufacturing, Cosmetic & Personal Care Products) - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global efficacy testing market is expected to reach USD 501.6 Million by 2022 from USD 330.5 Million in 2017, at a CAGR of 8.7%.

The increasing government support for pharmaceutical and biotechnology industries and R&D investments in the pharmaceutical sector are the key factors driving the growth of this market.

The global efficacy testing market is segmented by product and service, type, application, and region. By product and service, the market is segmented into consumables, services, and instruments. The consumables segment is estimated to account for the largest market share of the market in 2017. Factors driving the growth of this segment include regular and bulk purchases of consumables.

On the basis of type, the market is classified into antimicrobial efficacy testing and disinfectant efficacy testing. The disinfectant efficacy testing segment is estimated to account for the largest share of the market during the next five years. The applications of antimicrobial efficacy testing in the cosmetic, pharmaceutical, and medical device industries are driving the growth of this market.

On the basis of application, the market is classified into pharmaceutical manufacturing, cosmetic and personal care products and medical devices. The pharmaceutical manufacturing segment is estimated to account for the largest share of the market during the next five years. The large share of this segment can primarily be attributed to the increasing R&D expenditure by pharmaceutical companies and growth of the pharmaceutical industry.

The market is dominated by North America, followed by Europe. North America will continue to dominate the market during the forecast period. However, Asia is expected to witness the highest CAGR from 2017 to 2022. Factors such as the increasing government expenditure on healthcare, rising geriatric population, growing consumer health awareness, and increasing incidence of chronic diseases have boosted the demand for pharmaceutical products in this region. This will result in, increasing demand for efficacy testing products and services.

Eurofins Scientific (Luxembourg), Charles River Laboratories International (US), Becton, Dickinson and Company (US), SGS (Switzerland), Merck KGaA (Germany), bioMrieux (France), Pacific Biolabs (US), WuXi AppTec (China), North American Science Associates (US), and American Type Culture Collection (US) are some of the companies that provide products and services in this market.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Efficacy Testing Market, By Product & Service

7 Efficacy Testing Market, By Type

8 Efficacy Testing Market, By Application

9 Efficacy Testing Market, By Region

10 Competitive Landscape

11 Company Profiles

  • American Type Culture Collection
  • Becton Dickinson and Company
  • Biomrieux Sa
  • Charles River
  • Eurofins Scientific
  • Merck KGaA
  • North American Science Associates
  • Pacific Biolabs
  • SGS
  • Toxikon Corporation
  • Wuxi Apptec

For more information about this report visit https://www.researchandmarkets.com/research/xf8h39/global_efficacy?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



© 2018 PR Newswire
Vorsicht, geheim!
2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.